Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2024 | $32.00 | Perform → Outperform | Oppenheimer |
| 10/23/2023 | $60.00 | Mkt Outperform | JMP Securities |
| 9/29/2023 | $56.00 | Buy | UBS |
| 2/16/2022 | $120.00 → $88.00 | Buy | Canaccord Genuity |
| 2/16/2022 | $92.00 → $79.00 | Buy | Needham |
| 11/4/2021 | $90.00 → $92.00 | Buy | Needham |
| 11/4/2021 | $100.00 → $110.00 | Outperform | SVB Leerink |
| 8/5/2021 | $102.00 → $120.00 | Buy | Canaccord Genuity |
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
AtriCure (NASDAQ:ATRC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 2 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $40.17, with a high estimate of $49.00 and a low estimate of $32.00. A decline of 13.05% from the prior average price
Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $40 price target.
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - AtriCure, Inc. (0001323885) (Issuer)
10-Q - AtriCure, Inc. (0001323885) (Filer)
8-K - AtriCure, Inc. (0001323885) (Filer)
S-8 - AtriCure, Inc. (0001323885) (Filer)
4 - AtriCure, Inc. (0001323885) (Issuer)
Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage management devices in the U.S. International revenue of $20.5 million – an increase of 23.3% year over year Positive cash flow generation of $16.3 million in third quarter 2024 AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. "Our broad-based growth in the third quarter reflects strong, ongoing adop
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at h
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 financial results. "Our second quarter results reflect strong growth worldwide, underscored by our pain management and open AtriClip® franchises, as we continued to deliver exceptional patient outcomes across all therapies, while driving positive cash flow," said Michael Carrel, President and Chief Executive Officer at At
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2024 Healthcare Conference. AtriCure's management is scheduled to participate in a fireside chat on Monday, November 18, 2024, at 9:10 am Eastern Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at https://ir.atricure.com About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditio
Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage management devices in the U.S. International revenue of $20.5 million – an increase of 23.3% year over year Positive cash flow generation of $16.3 million in third quarter 2024 AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. "Our broad-based growth in the third quarter reflects strong, ongoing adop
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at https://ir.atricure.com About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditio
Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00
JMP Securities initiated coverage of AtriCure with a rating of Mkt Outperform and set a new price target of $60.00
UBS initiated coverage of AtriCure with a rating of Buy and set a new price target of $56.00